Filing Flows › Puma Biotechnology (PBYI) › Royalty revenue
Puma Biotechnology (PBYI) Royalty revenue by quarter
Puma Biotechnology's Royalty revenue was $944K in Q3 2026 (third quarter 2026), -68% from Q2 2026. Over the last 7 quarters it ranged from $944K (Q3 2026) to $15.6M (Q4 2025).
| Quarter | Royalty revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $944K | -68% | -63% |
| Q2 2026 | $2.9M | +3% | -9% |
| Q1 2026 | $2.9M | -82% | -2% |
| Q4 2025 | $15.6M | +505% | — |
| Q3 2025 | $2.6M | -21% | — |
| Q2 2025 | $3.2M | +12% | — |
| Q1 2025 | $2.9M | — | — |
Q3 2026 at a glance
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M, operating cash flow $14.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Puma Biotechnology's Royalty revenue?
Puma Biotechnology's Royalty revenue was $944K in Q3 2026 (third quarter 2026), -68% from Q2 2026.
How has Puma Biotechnology's Royalty revenue changed?
Over the last 7 quarters it ranged from $944K (Q3 2026) to $15.6M (Q4 2025).